AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 121 min read$HRMY

Harmony Biosciences appoints Peter Anastasiou as CEO (HRMY:NASDAQ)

Harmony Biosciences (HRMY) named Peter Anastasiou as CEO and board member, effective January 1, 2027. He will succeed Jeffrey Dayno, who is retiring.

Original reporting
seekingalpha.com
Published Oct 12, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$HRMY
Neutral
high confidence
Mentioned
$HRMY
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$HRMYNeutralLow
01

Why it matters

The appointment is a standard corporate action with limited immediate market impact, but investors will watch for any strategic direction changes.

02

Market read

Exec change is a modest catalyst; traders may monitor for follow‑up guidance or strategic announcements.

03

What to watch

Potential hidden strategic shifts or cost‑cutting measures not disclosed yet.

Relevance 7/10Novelty 6/10Timing: today

Background

Harmony Biosciences (HRMY) is a clinical‑stage biotech focused on rare diseases. The outgoing CEO, Jeffrey Dayno, is retiring.

Company-level read

Ticker impact

$HRMYNeutralHigh confidence
Context

Harmony Biosciences announced the appointment of Peter Anastasiou as President, CEO and Board member, effective Jan 1, 2027.

Expected impact

likely limited movement as market prices in the appointment.

Evidence & confidence

Executive changes are common and usually do not cause immediate price swings unless accompanied by strategic announcements.

Market effects

Sector

Minimal; biotech sector may view the change as routine.

Regional

None

Global

Low

Counterpoint

What could challenge this read

If Anastasiou brings a bold turnaround plan, the stock could rally on optimism.

Key entities

  • person
    Peter Anastasiou

    New President, CEO and Board member of Harmony Biosciences.

  • person
    Jeffrey Dayno

    Outgoing President and CEO of Harmony Biosciences.

Read at source← All news

StoryHarmony Biosciences names COO Peter Anastasiou as CEO effective Jan 1 2027

Also covered by

2 outlets

Related articles

OCT 12
$HRMYHigh

Why Harmony Biosciences Stock Got Mashed on Monday

Harmony Biosciences (HRMY) shares fell over 5% after announcing COO Peter Anastasiou will become CEO in 2027, replacing Jeffrey Dayno. The company reaffirmed its full-year revenue guidance for Wakix at $1B-$1.04B and maintained its strategic priorities. Dayno will stay in an advisory role.

finance.yahoo.com2 min
OCT 12
$HRMYMed

Why is Harmony Biosciences stock sliding today?

Harmony Biosciences (HRMY) shares fell 5.2% after announcing CEO succession plans. Current COO Peter Anastasiou will replace Jeffrey M. Dayno in 2027. The company reiterated its 2026 revenue guidance of $1.0B-$1.04B for WAKIX and confirmed pipeline data release timelines. The stock's decline was attributed to market caution around leadership changes and existing investor concerns.

investing.com5 min
OCT 12
$HRMYLow

Harmony Biosciences names Peter Anastasiou as next CEO

Harmony Biosciences (HRMY) named Peter Anastasiou as its next CEO, effective January 1, 2027. He will succeed Jeffrey M. Dayno, who will retire at the end of 2026. Anastasiou is currently the company's COO and previously served on its board. The company reiterated its 2026 revenue guidance of $1.0B to $1.04B for WAKIX. Anastasiou's background includes leadership roles at Capsida Biotherapeutics and Lundbeck.

investing.com2 min
SEP 3
$HRMYHighAI 8/10

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.

finance.yahoo.com2 min
AUG 11
$HRMYMedAI 8/10

Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript

Harmony Biosciences (HRMY) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and confirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million ($1.28/diluted share). Cash and investments were $962.5 million as of June 30, 2026. The company also discussed BP-205 clinical data and pipeline timelines.

fool.com10 min